FDA Sends Letter To California Company Marketing Injectable CBD, “Your “Pico IV” product is especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users.”

Header Image:J oe Young CEO @ PICO IV Inc. The Letter WARNING LETTER Pico IV Inc.MARCS-CMS 700591 — March 06, 2025 Delivery Method: Via Email Product: Drugs Recipient: Joseph Young CEO Pico IV Inc. 1610 R St. Ste 300Sacramento, CA 95811United States  Support@picoiv.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER March 6, […]